Updated:
R-Biopharm
R-Biopharm was carved out of Röhm GmbH in 1988 and taken private by Dr. Ralf M. Dreher via a management buyout in 1991. The Dreher family controls the...
R-Biopharm
R-Biopharm was carved out of Röhm GmbH in 1988 and taken private by Dr. Ralf M. Dreher via a management buyout in 1991. The Dreher family controls the Darmstadt-based group through HRT Beteiligungs GmbH & Co. KG, having bought out minority shareholder BWK GmbH in 2022. The firm unites R&D, production, and distribution at its headquarters, with 29 subsidiaries and 120 distributors spanning the US, UK, France, Italy, China, India, and Brazil. Capital is deployed as a corporate investor backing early-stage diagnostic and life-science tools startups that complement its core portfolio. Core commercial franchises include clinical IVD kits, food and feed allergen testing systems — where the company claims global market leadership in allergen analysis — and a nutrition care unit pairing diagnostics with individualized wellness programs. R-Biopharm reached a landmark in June 2022 when it gained IVDR 2017/746 certification, while its 2022 acquisition of Sydney-based AusDiagnostics added proprietary multiplex molecular biology platforms to the group's consolidated "Made in Germany" manufacturing backbone. The group employs more than 1,400 people worldwide and operates from a purpose-built Darmstadt campus with additional real-estate holdings in Bensheim and Pfungstadt. R-Biopharm Inc., its US subsidiary in Washington, Missouri, provides American distribution. Dr. Ralf Dreher handed the chairmanship to Christian Dreher in 2018 as part of a deliberate family succession. June 2022 brought two milestones: the AusDiagnostics acquisition and full IVDR certification. Philanthropic activities are organized under the Waldoni Kinder- und Jugendstiftung foundation. The firm differentiates through vertical integration rarely seen among mid-market biotech peers. By keeping research, development, and production under one roof, R-Biopharm shortens the feedback loop between in-house manufacturing and regulatory cycles — a structural advantage when competing against larger CRO-dependent platforms. This architecture allows the Dreher family to reinvest free cash flow into bolt-on acquisitions and early-stage corporate venture deals without external LP constraints.
General information
Firm type
Corporate Investor
Year founded
1988
AUM
Undisclosed
Location
Region
Europe
Country
Germany
City
Darmstadt
Corporate office
An der neuen Bergstraße 17, 64297 Darmstadt, Germany
Additional offices
Washington, MO, United States · Pfungstadt, Germany · Bensheim, Germany
Principals
Christian Dreher
CEO
Dr. Ralf M. Dreher
Founder
Sector focus
Frequently asked questions
Who owns R-Biopharm?
The Dreher family controls R-Biopharm through HRT Beteiligungs GmbH & Co. KG. Founder Dr. Ralf M. Dreher acquired the business from Röhm GmbH in a 1991 management buyout and later bought out the minority shareholder BWK GmbH in 2022, making it fully family-owned. Christian Dreher, son of the founder, has been CEO since 2018.
What is R-Biopharm's corporate venture strategy?
R-Biopharm operates as a corporate investor, allocating operating-company cash flows to early-stage biotechnology and diagnostic-tool startups aligned with its core clinical and food-analysis portfolio. The firm targets deals that extend its vertical-integration model, favoring technologies that can be scaled through its own manufacturing and distribution infrastructure.
Does R-Biopharm have a private equity or external LP arm?
No. R-Biopharm's investment activity is funded entirely from its balance sheet and operating cash flows. It does not manage external limited-partner capital or operate a separate venture-capital vehicle, which distinguishes it from many healthcare-focused institutional investors.
Which sectors does R-Biopharm explicitly avoid?
The firm's entire disclosed footprint — from commercial kits to corporate venture bets — stays within clinical diagnostics, food and feed analysis, and nutrition care. It has no known presence in therapeutics, drug discovery, agricultural biotechnology outside the food-safety chain, or pure-play health-tech software.
How is R-Biopharm's philanthropy structured?
Philanthropic activities are housed in the Waldoni Kinder- und Jugendstiftung, a foundation focused on children and youth. Governance is kept separate from the commercial group, maintaining a clear boundary between charitable disbursements and the balance sheet used for corporate venture investments.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: